Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation.
Two subtypes of G-protein-coupled cannabinoid receptors have been identified to date: the CB1 central receptor subtype, which is mainly expressed in the brain, and the CB2 peripheral receptor subtype, which appears particularly abundant in the immune system. We investigated the expression of CB2 receptors in leukocytes using anti-CB2 receptor immunopurified polyclonal antibodies. We showed that peripheral blood and tonsillar B cells were the leukocyte subsets expressing the highest amount of CB2 receptor proteins. Dual-color confocal microscopy performed on tonsillar tissues showed a marked expression of CB2 receptors in mantle zones of secondary follicles, whereas germinal centers (GC) were weakly stained, suggesting a modulation of this receptor during the differentiation stages from virgin B lymphocytes to memory B cells. Indeed, we showed a clear downregulation of CB2 receptor expression during B-cell differentiation both at transcript and protein levels. The lowest expression was observed in GC proliferating centroblasts. Furthermore, we investigated the effect of the cannabinoid agonist CP55,940 on the CD40-mediated proliferation of both virgin and GC B-cell subsets. We found that CP55,940 enhanced the proliferation of both subsets and that this enhancement was blocked by the CB2 receptor antagonist SR 144528 but not by the CB1 receptor antagonist SR 141716. Finally, we observed that CB2 receptors were dramatically upregulated in both B-cell subsets during the first 24 hours of CD40-mediated activation. These data strongly support an involvement of CB2 receptors during B-cell differentiation.
Carayon
P
P
Immunology Department, Sanofi Recherche, Montpellier, France; and the Immunité et vaccination, INSERM U404, Institut Pasteur de Lyon, Lyon, France. catherine.carayon@tls1.elfsanofi.fr
Marchand
J
J
Dussossoy
D
D
Derocq
J M
JM
Jbilo
O
O
Bord
A
A
Bouaboula
M
M
Galiègue
S
S
Mondière
P
P
Pénarier
G
G
Fur
G L
GL
Defrance
T
T
Casellas
P
P
D000818:Animals; D016175:B-Lymphocyte Subsets / Q000166:cytology* / Q000378:metabolism; D019013:CD40 Antigens / Q000502:physiology; D016466:CHO Cells; D001892:Camphanes / Q000494:pharmacology; D002454:Cell Differentiation; D006224:Cricetinae; D003412:Cricetulus; D003511:Cyclohexanols / Q000494:pharmacology; D018858:Germinal Center / Q000166:cytology; D006801:Humans; D018613:Microscopy, Confocal; D014066:Palatine Tonsil / Q000166:cytology; D010446:Peptide Fragments / Q000276:immunology; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D011817:Rabbits; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000187:drug effects / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D011993:Recombinant Fusion Proteins / Q000502:physiology; D000077285:Rimonabant; D014162:Transfection
D019013:CD40 Antigens; D001892:Camphanes; D003511:Cyclohexanols; D010446:Peptide Fragments; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D011993:Recombinant Fusion Proteins; C110630:SR 144528; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; D000077285:Rimonabant